Numab

Numab Therapeutics AG

Business Model
B2B
Website
numab.com
Total Funding
$165.0M
Last Round
$55.0M Extension RoundJan 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Numab Therapeutics AG is a clinical-stage Swiss biotech that designs multi-specific antibody medicines with proprietary λ-Cap and MATCH platforms. Its plug-and-play therapeutic design process is meant to overcome historical drug-discovery barriers and yield first-in-class and best-in-class treatments for patients with chronic inflammation and cancer. Numab collaborates with partners such as Boehringer Ingelheim on multi-specific antibodies and advanced pipeline candidate NM26, an anti-IL4R/IL-31 antibody acquired by Johnson & Johnson in 2024.

Summary

Numab is a Biotech company. It has raised $165.0M in total across 2 rounds, most recently a $55.0M Extension Round in Jan 2025. Investors include Novo Holdings A/S, HBM Partners and Forbion Capital Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundSeries C ExtensionJan 2025
$55.0M

Sign up to see all 2 events

Funding: Series C through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Numab on Indexed.vc
<a href="https://indexed.vc/companies/numab"><img src="https://indexed.vc/api/badge/company/numab" alt="Numab on Indexed.vc" width="260" height="76" /></a>